MAFLD – Exercise as Liver Therapy

Table of Contents

1. From NAFLD to MAFLD – Defining the Disease
2. Mechanisms of High-Intensity Exercise in MAFLD
3. Clinical Outcomes and Biomarkers Improved by HIIT
4. Typical HIIT Prescription for MAFLD
5. Protein-Enriched Diet and Exercise Snacks
6. The Exercise and Sport Science Australia Position Statement
7. Synthesis – Liver as an Exercise-Responsive Organ

---

1 From NAFLD to MAFLD – Defining the Disease

Terminology

What was historically called non-alcoholic fatty liver disease (NAFLD) has been reframed as metabolic-associated fatty liver disease (MAFLD) to emphasise its causal link with metabolic dysfunction rather than its exclusion of alcohol [1, 2]. The MAFLD diagnosis requires hepatic steatosis plus at least one of:

• overweight or obesity,
• type 2 diabetes,
• evidence of metabolic dysfunction (insulin resistance, dyslipidaemia, hypertension, or biomarker abnormality).

The change in nomenclature reflects a change in clinical posture: MAFLD is understood as a hepatic manifestation of the same systemic metabolic process that produces prediabetes, type 2 diabetes and the metabolic syndrome — themes developed in Lectures 4 and 5.

Disease Spectrum

MAFLD spans a clinically important spectrum [1]:

1. Simple steatosis — increased hepatic triglyceride, generally non-progressive.
2. Steatohepatitis (NASH / MASH) — inflammation and hepatocellular ballooning, with potential for progression.
3. Fibrosis — staged F0–F4; the strongest histological predictor of liver-related and overall mortality.
4. Cirrhosis — F4 fibrosis with architectural distortion; complications include portal hypertension and hepatocellular carcinoma.

Exercise intervention is most strongly evidenced for steatosis reduction and improvement of metabolic and inflammatory biomarkers; effects on fibrosis stage are encouraging but require longer follow-up.

---

2 Mechanisms of High-Intensity Exercise in MAFLD

Human Adipose and Systemic Metabolic Shifts

HIIT produces tissue-specific metabolite changes in human adipose tissue and the systemic circulation [2]. Amino acid profiles and glyco-conjugated bile acids change in patterns that correlate with clinical improvements:

• reduced fasting glucose,
• reduced waist circumference,
• improved V̇O₂max,
• improved hepatic biomarkers after 12 weeks of structured HIIT.

The pattern suggests that adipose-driven metabolic signalling contributes to the liver benefit — i.e., the exercise effect on the liver is partly indirect, mediated through the metabolic re-tuning of adipose tissue.

Hepatic Fatty Acid Oxidation and Reduced Lipogenesis

Pre-clinical work in rodent models shows that HIIT — alone and in combination with intermittent fasting — enhances hepatic fatty acid oxidation and reduces hepatic de novo lipogenesis [2]. The relevant transcriptional regulators include:

• PGC-1α — mitochondrial biogenesis, fatty acid oxidation.
• PPAR-α — fatty acid oxidation in liver and muscle.
• AMPK — energy-sensing, suppression of lipogenic SREBP-1c.

The combination of increased oxidation and reduced lipogenesis is the cellular basis for the macroscopic reduction in hepatic fat content seen on imaging.

Anti-Inflammatory Effects in the Liver

Exercise reduces hepatic inflammatory tone through the same exerkine-mediated mechanisms described in Lecture 8:

• lower visceral adiposity → lower portal cytokine load,
• shift in hepatic macrophage (Kupffer cell) phenotypes toward anti-inflammatory states,
• reduced ROS leakage from improved mitochondrial coupling.

---

3 Clinical Outcomes and Biomarkers Improved by HIIT

A Quantitative Summary

Domain	Biomarker	Direction and approximate magnitude
Liver	Liver fat (MRI-PDFF)	↓ ≈ 2.85 % absolute (representative trials)
Liver	ALT	↓ ≈ 2.4 U/L
Liver	AST	↓ small but consistent
Metabolic	Insulin sensitivity	↑
Metabolic	HOMA-IR	↓
Metabolic	Fasting glucose	↓
Fitness	V̇O₂max	↑ ≈ 10–20 %
Anthropometric	Waist circumference	↓

Table 1. Key quantitative improvements observed with HIIT in MAFLD. Values are approximate from representative trials and reviews; magnitudes depend on the prescription, duration and baseline severity (synthesised from [2]).

Why These Outcomes Matter

The most robust markers of MAFLD prognosis are fibrosis stage, liver fat content and integrated metabolic burden. Exercise modifies the latter two reliably; whether structured HIIT modifies fibrosis directly is plausible but not yet definitively established at the histological level in large RCTs.

The clinical implication: HIIT should be routinely prescribed in MAFLD because it improves multiple intermediate outcomes, even where direct fibrosis-modifying effects await stronger evidence.

---

4 Typical HIIT Prescription for MAFLD

The 4 × 4 Format

The most evidence-supported HIIT prescription in MAFLD trials is the 4 × 4 minute interval protocol [2]:

• 3-minute warm-up at ≈ 60 % HRpeak.
• 4 minutes at 85–95 % HRpeak — the work interval.
• 3-minute active recovery at ≈ 60 % HRpeak.
• Repeat 4 times for a total of 16 minutes of work and ~ 28 minutes session time (including warm-up and cool-down).
• Frequency: 3 sessions per week.
• Duration: 8–12+ weeks for measurable hepatic and metabolic improvement.

Phase	Duration	Intensity
Warm-up	3 min	60 % HRpeak
Work interval	4 min	85–95 % HRpeak
Active recovery	3 min	60 % HRpeak
Repeats	4	—
Sessions per week	3	—
Total programme	8–12+ weeks	—

Table 2. Typical HIIT prescription for MAFLD (synthesised from [2]).

Practical Considerations

• Pre-exercise screening is essential, particularly for cardiovascular risk in older patients.
• Modality can be cycling, brisk walking on incline, or rowing — the prescription is intensity-defined, not modality-defined.
• HR target can be substituted with RPE 16–18 if HR is unreliable (β-blockers, atrial fibrillation).
• Progression: start at the lower end of the work-interval range (85 % HRpeak) and progress.

Practical insight. A 30-minute HIIT session, three times per week, fits within the time budgets of most working adults and produces measurable hepatic improvement — making it perhaps the highest-yield single intervention for MAFLD outside of weight loss itself.

---

5 Protein-Enriched Diet and Exercise Snacks

Adequate Protein Intake

Adequate protein intake is crucial for maintaining muscle mass and supporting liver regeneration, especially during weight-loss interventions in MAFLD [3]. The mechanisms:

• Higher protein intake reduces sarcopenic loss during caloric deficit.
• Preserved muscle mass supports the contraction-mediated GLUT4 pathway (Lecture 4) and overall metabolic rate.
• Branched-chain amino acids contribute to hepatic regeneration.

Isocaloric High-Protein Diets

A 6-week isocaloric high-protein diet — whether meat-and-dairy-based or legume-based — produced comparable improvements in hepatic markers and body composition in MAFLD trials [3]. The implication: plant-based high-protein patterns are a credible alternative to animal-based patterns for MAFLD management.

Combining Protein, HIIT and Exercise Snacks

A pragmatic combination for the MAFLD patient is:

1. 3 × HIIT sessions per week (4 × 4 format, Section 4).
2. Daily exercise snacks (Lecture 6) — three short vigorous bouts to reduce post-prandial glucose excursions.
3. Higher protein intake across the day, distributed across meals.
4. Reduced sedentary time — break up sitting every 30 minutes (Lecture 5).
5. Sleep stabilisation (Lecture 2).

---

6 The Exercise and Sport Science Australia Position Statement

Source

Keating, Sabag, Hallsworth, Hickman, Macdonald, Stine, George and Johnson [2] published the Exercise and Sport Science Australia (ESSA) position statement on exercise in the management of MAFLD in adults in 2023.

Key Recommendations

The ESSA position statement endorses:

1. Aerobic exercise — including moderate-intensity continuous training (MICT) and HIIT — as first-line lifestyle intervention.
2. Resistance training — at least 2 sessions per week to support muscle mass preservation and metabolic benefit.
3. Reduction of sedentary time — consistent with the Dunstan framework (Lecture 5).
4. Combination with dietary intervention — particularly Mediterranean-style and high-protein patterns.
5. Individualised prescription — by baseline fitness, comorbidity profile, and patient preference.

The position statement is intentionally pragmatic: most MAFLD patients can be managed with a structured but accessible exercise prescription, and the evidence base is sufficient for routine clinical recommendation.

---

7 Synthesis – Liver as an Exercise-Responsive Organ

Take-Home Principles

1. MAFLD is a hepatic manifestation of systemic metabolic dysfunction. It responds to the same prescription levers as prediabetes and the metabolic syndrome.
2. HIIT — particularly the 4 × 4 format — is the best-evidenced single exercise intervention for MAFLD, with reproducible improvements in liver fat, ALT, insulin sensitivity and V̇O₂max.
3. Exercise effects on the liver are partly indirect — mediated through adipose-driven metabolic signalling and through reduction in visceral adiposity.
4. Protein-adequate, plant-friendly diets complement the exercise prescription, particularly during weight loss.
5. Fibrosis-modifying effects are plausible but await stronger longitudinal evidence; intermediate outcomes are nonetheless clinically meaningful.

Connection to the Lecture Series

• Lecture 4–5: prediabetes, metabolic syndrome, visceral adiposity — the metabolic upstream of MAFLD.
• Lecture 6: exercise snacks integrated into the MAFLD prescription package.
• Lecture 7: intensity prescription anchors (HR, RPE, MET) applied to HIIT.
• Lecture 10–11: parallel framework applied to IBD.
• Lecture 12: hepatokines and exerkines as the connecting messengers.

---

References

• [1] Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
• [2] Keating SE, Sabag A, Hallsworth K, Hickman IJ, Macdonald GA, Stine JG, George J, Johnson NA. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from Exercise and Sport Science Australia. Sports Medicine. 2023;53(12):2347–2371. doi:10.1007/s40279-023-01918-w.
• [3] Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association. 2013;14(8):542–559.
• [4] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. Journal of Hepatology. 2017;66(1):142–152.
• [5] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. Journal of Hepatology. 2020;73(1):202–209.
• [6] Stine JG, Long MT, Corey KE, et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatology Communications. 2023;7(4):e0108.

---

One-Minute-Paper Topics

1. State the new MAFLD diagnostic criteria and explain why the field shifted from NAFLD to MAFLD.
2. List the four stages of the MAFLD disease spectrum and identify the strongest histological predictor of liver-related mortality.
3. Describe two mechanisms by which HIIT reduces hepatic fat content.
4. Why is the exercise effect on the liver described as “partly indirect”? Name the mediating tissue.
5. Identify three transcriptional regulators activated by exercise that drive hepatic fatty acid oxidation.
6. Reproduce Table 1: which biomarkers improve with HIIT in MAFLD, and by approximately how much?
7. Detail the 4 × 4 HIIT protocol from memory: warm-up, work interval, active recovery, repeats, frequency, duration.
8. For a 55-year-old MAFLD patient on β-blockers, how would you adapt the HR-defined HIIT prescription?
9. Why is muscle mass preservation important during weight loss in MAFLD? What protein intake guidance follows?
10. Compare animal-protein and legume-protein diets in MAFLD management based on the 6-week isocaloric trial described in Section 5.
11. Summarise the ESSA position statement in three sentences.
12. Why is fibrosis modification by exercise still an open question? What study design would answer it definitively?
13. Sketch a pragmatic 8-week MAFLD prescription combining HIIT, exercise snacks, sedentary-time interruption and dietary advice.
14. Identify two patient subgroups for whom the standard 4 × 4 HIIT protocol may need modification (give reasons).
15. Describe how Kupffer-cell phenotype shifts mediate hepatic anti-inflammatory effects of exercise.
16. Why is MAFLD considered the hepatic manifestation of the metabolic syndrome (cf. Lecture 5)?
17. The “adipose-liver axis” is invoked in this lecture. Identify one circulating signal that connects adipose-driven changes to hepatic improvement.
18. Compare MICT and HIIT for hepatic fat reduction in MAFLD. Which is more time-efficient, and which is more accessible?
19. Sketch the longitudinal outcome trajectory you would expect for a MAFLD patient committed to 12 weeks of HIIT + dietary change.
20. Identify three open research questions in exercise-MAFLD medicine that are most clinically pressing.